Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo

Journal of Hepatology

Volumn 50, Issue 6, 2009, Pages 1112-1121

  Lai, Jin Ping ^a   Sandhu, Dalbir S ^a   Moser, Catherine D ^a   Cazanave, Sophie C ^a   Oseini, Abdul M ^a   Shire, Abdirashid M ^a   Shridhar, Viji ^a   Sanderson, Schuyler O ^a   Roberts, Lewis R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Akt kinase; Apoptosis; Doxorubicin; Hepatocellular carcinoma; Histone deacetylase inhibitor; MAP kinase; Sulfatase 1 (SULF1)

Indexed keywords

APICIDIN; CASPASE; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN KINASE B; SULFATASE; SULFATASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PEPTIDES, CYCLIC; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS; SULFOTRANSFERASES; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 67349286240     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.12.031     Document Type: Article

References (42)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 (2004) S27-S34
3. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
4. Abou-Alfa G.K., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 4293-4300
5. Llovet J.M., Di Bisceglie A.M., Bruix J., Kramer B.S., Lencioni R., Zhu A.X., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100 (2008) 698-711
6. Zhu W.G., and Otterson G.A. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents 3 (2003) 187-199
7. Lai J.P., Yu C., Moser C.D., Aderca I., Han T., Garvey T.D., et al. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. Gastroenterology 130 (2006) 2130-2144
8. Ueda T., Takai N., Nishida M., Nasu K., and Narahara H. Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells. Int J Mol Med 19 (2007) 301-308
9. Kim Y.K., Han J.W., Woo Y.N., Chun J.K., Yoo J.Y., Cho E.J., et al. Expression of p21(WAF1/Cip1) through Sp1 sites by histone deacetylase inhibitor apicidin requires PI 3-kinase-PKC epsilon signaling pathway. Oncogene 22 (2003) 6023-6031
10. Lai J.P., Chien J.R., Moser D.R., Staub J.K., Aderca I., Montoya D.P., et al. hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 126 (2004) 231-248
11. Lai J., Chien J., Staub J., Avula R., Greene E.L., Matthews T.A., et al. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 278 (2003) 23107-23117
12. Lai J.P., Chien J., Strome S.E., Staub J., Montoya D.P., Greene E.L., et al. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 23 (2004) 1439-1447
13. Li J., Kleeff J., Abiatari I., Kayed H., Giese N.A., Felix K., et al. Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Mol Cancer 4 (2005) 14
14. Narita K., Staub J., Chien J., Meyer K., Bauer M., Friedl A., et al. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res 66 (2006) 6025-6032
15. Narita K., Chien J., Mullany S.A., Staub J., Qian X., Lingle W.L., et al. Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J Biol Chem 282 (2007) 14413-14420
16. Dahl E., Kristiansen G., Gottlob K., Klaman I., Ebner E., Hinzmann B., et al. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res 12 (2006) 3950-3960
17. Abiatari I., Kleeff J., Li J., Felix K., Buchler M.W., and Friess H. Hsulf-1 regulates growth and invasion of pancreatic cancer cells. J Clin Pathol 59 (2006) 1052-1058
18. Backen A.C., Cole C.L., Lau S.C., Clamp A.R., McVey R., Gallagher J.T., et al. Heparan sulphate synthetic and editing enzymes in ovarian cancer. Br J Cancer 96 (2007) 1544-1548
19. Staub J., Chien J., Pan Y., Qian X., Narita K., Aletti G., et al. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. Oncogene 26 (2007) 4969-4978
20. Dai Q., Qian S.B., Li H.H., McDonough H., Borchers C., Huang D., et al. Regulation of the cytoplasmic quality control protein degradation pathway by BAG2. J Biol Chem 280 (2005) 38673-38681
21. Lin D.Y., Lin S.M., and Liaw Y.F. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 12 (1997) S319-S328
22. Yang T.S., Lin Y.C., Chen J.S., Wang H.M., and Wang C.H. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 89 (2000) 750-756
23. Choi J., Yip-Schneider M., Albertin F., Wiesenauer C., Wang Y., and Schmidt C.M. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC. J Surg Res 150 (2008) 219-226
24. Huynh H., Chow P.K., and Soo K.C. AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther 6 (2007) 2468-2476
25. Almhanna K., Kalmadi S., Pelley R., and Kim R. Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?. Oncology (Williston Park) 21 (2007) 1116-1122
26. Kerr J.F., Winterford C.M., and Harmon B.V. Apoptosis. Its significance in cancer and cancer therapy. Cancer 73 (1994) 2013-2026
27. Potten C.S. What is an apoptotic index measuring? A commentary. Br J Cancer 74 (1996) 1743-1748
28. Arai T., and Kino I. Role of apoptosis in modulation of the growth of human colorectal tubular and villous adenomas. J Pathol 176 (1995) 37-44
29. Sinicrope F.A., Roddey G., McDonnell T.J., Shen Y., Cleary K.R., and Stephens L.C. Increased apoptosis accompanies neoplastic development in the human colorectum. Clin Cancer Res 2 (1996) 1999-2006
30. Hawkins N.J., Lees J., and Ward R.L. Detection of apoptosis in colorectal carcinoma by light microscopy and in situ end labelling. Anal Quant Cytol Histol 19 (1997) 227-232
31. Koornstra J.J., Rijcken F.E., De Jong S., Hollema H., de Vries E.G., and Kleibeuker J.H. Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas. Histopathology 44 (2004) 9-17
32. Lai J.P., Tong C.L., Hong C., Xiao J.Y., Tao Z.D., Zhang Z., et al. Association between high initial tissue levels of cyclin d1 and recurrence of nasopharyngeal carcinoma. Laryngoscope 112 (2002) 402-408
33. Yu C., Subler M., Rahmani M., Reese E., Krystal G., Conrad D., et al. Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. Cancer Biol Ther 2 (2003) 544-551
34. Han J.W., Ahn S.H., Park S.H., Wang S.Y., Bae G.U., Seo D.W., et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 60 (2000) 6068-6074
35. Cheong J.W., Chong S.Y., Kim J.Y., Eom J.I., Jeung H.K., Maeng H.Y., et al. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells. Clin Cancer Res 9 (2003) 5018-5027
36. Kim S.H., Ahn S., Han J.W., Lee H.W., Lee H.Y., Lee Y.W., et al. Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem Biophys Res Commun 315 (2004) 964-970
37. Kwon S.H., Ahn S.H., Kim Y.K., Bae G.U., Yoon J.W., Hong S., et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 277 (2002) 2073-2080
38. Schiffer E., Housset C., Cacheux W., Wendum D., Desbois-Mouthon C., Rey C., et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41 (2005) 307-314
39. Camp E.R., Summy J., Bauer T.W., Liu W., Gallick G.E., and Ellis L.M. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11 (2005) 397-405
40. Datta S.R., Brunet A., and Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev 13 (1999) 2905-2927
41. Clark A.S., West K., Streicher S., and Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1 (2002) 707-717
42. Sridhar S.S., Hedley D., and Siu L.L. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4 (2005) 677-685